Andexanet alfa - Alexion AstraZeneca Rare Disease
Alternative Names: ALXN 2070; ANDEXXA; AndexXa; Coagulation factor Xa (recombinant), inactivated-zhzo; IndexXa; Ondexa; Ondexxya; PRT-064445; PRT-4445; PRT-44545; r-antidote; Recombinant factor-Xa-Portola; rfXa-inhibitor-antidoteLatest Information Update: 05 Nov 2023
At a glance
- Originator Portola Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease
- Class Antidotes; Antihaemorrhagics; Disulfides; Recombinant proteins
- Mechanism of Action Blood coagulation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemorrhage
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 03 Jul 2023 Registered for Haemorrhage in Australia (IV)
- 05 Jun 2023 AstraZeneca plans to submit regulatory filings to convert from conditional to full approval of andexanet alfa in the US and EU